Strattera, a
selective norepinephrine reuptake inhibitor, is approved for both pediatric and adult patients.
SPN-812 is a
selective norepinephrine reuptake inhibitor that the company believes could be more effective and with an improved side effect profile compared to other non-stimulant treatments for ADHD due to its different pharmacological profile.
Between 5% and 14% of patients on a selective serotonin reuptake inhibitor (SSRI) or a
selective norepinephrine reuptake inhibitor (SNRI) develop drug-induced excessive sweating.
Reboxetine is a
selective norepinephrine reuptake inhibitor used in the United Kingdom.
Major finding: Patients with depression who did not respond adequately to a course of selective serotonin reuptake inhibitor or
selective norepinephrine reuptake inhibitor therapy and who were then switched to double-blind treatment with the novel antidepressant vortioxetine had a 55% remission rate after 8 weeks of therapy.
Strattera, a
selective norepinephrine reuptake inhibitor, works differently than other FDA-approved treatments for the disorder, all of which are stimulants.
Stimulants such as methylphenidate, amphetamines, and pemoline, as well as the
selective norepinephrine reuptake inhibitor atomoxetine, are known to raise heart rate and to increase systolic blood pressure by approximately 2-5 mm Hg and diastolic blood pressure by 1-3 mm Hg.
Physicians and patients may be alarmed by recent changes to the product labels of the selective serotonin reuptake inhibitors and the
selective norepinephrine reuptake inhibitor venlafaxine with respect to their use during pregnancy.
Tomoxetine, a
selective norepinephrine reuptake inhibitor, has been shown to be effective for adult ADHD in double-blind crossover studies.
In late July, the FDA issued an approvable letter regarding reboxetine, a
selective norepinephrine reuptake inhibitor, for the treatment of depression.
In late July, the FDA issued an "approvable letter" regarding reboxetine, a
selective norepinephrine reuptake inhibitor, for the treatment of depression.
Strattera, a
selective norepinephrine reuptake inhibitor, works differently than any older FDA-approved treatments for the disorder, all of which are stimulants.
